Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PhaseBio Pharmaceuticals (PHAS : NSDQ)

• Company Description    PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States. Number of Employees: 60

• Price / Volume Information    Yesterday's Closing Price: $0.93 Daily Weekly Monthly 20 Day Moving Average: 539,956 shares Shares Outstanding: 48.69 (millions) Market Capitalization: $45.28 (millions) Beta: 1.98 52 Week High: $4.24 52 Week Low: $0.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.40% -17.16% 12 Week -29.01% -22.98% Year To Date -64.37% -57.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 Great Valley Parkway Suite 30 - Malvern,PA 19355 USA ph: 610-981-6500 fax: - john.sharp@phasebio.com http://www.phasebio.com

• General Corporate Information    Officers Jonathan P. Mow - Chief Executive Officer Clay B. Thorp - Chairman John P. Sharp - Chief Financial Officer Edmund P. Harrigan - Director Nancy J. Hutson - Director Peer Information PhaseBio Pharmaceuticals (CORR.) PhaseBio Pharmaceuticals (RSPI) PhaseBio Pharmaceuticals (CGXP) PhaseBio Pharmaceuticals (BGEN) PhaseBio Pharmaceuticals (GTBP) PhaseBio Pharmaceuticals (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 717224109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 48.69 Most Recent Split Date: (:1) Beta: 1.98 Market Capitalization: $45.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.14 EPS Growth vs. Year Ago Period: 73.56% vs. Previous Quarter: 74.44% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -25.95% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -144.23 12/31/21 - -154.33 09/30/21 - -143.64 Current Ratio 03/31/22 - - 12/31/21 - 1.75 09/30/21 - 3.04 Quick Ratio 03/31/22 - - 12/31/21 - 1.75 09/30/21 - 3.04 Operating Margin 03/31/22 - -1,049.18 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - -1,049.18 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -1,195.37 09/30/21 - -1,093.85 Book Value 03/31/22 - - 12/31/21 - -1.93 09/30/21 - -1.05 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©